van Besien K - Search Results

1

Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment.

van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. van Besien K, et al. Leuk Lymphoma. 2008;49 Suppl 1:52-8. doi: 10.1080/10428190802311458. Leuk Lymphoma. 2008. PMID: 18821433 Review.

2

Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant.

van Besien K, Smith S, Lazarus HM. van Besien K, et al. Curr Treat Options Oncol. 2005 Jul;6(4):279-87. doi: 10.1007/s11864-005-0032-z. Curr Treat Options Oncol. 2005. PMID: 15967081 Review.

3

Toxicity of high dose BCNU: how much is too much?

van Besien K. van Besien K. Leuk Lymphoma. 2006 Aug;47(8):1447-8. doi: 10.1080/10428190600725495. Leuk Lymphoma. 2006. PMID: 16966249 No abstract available.

4

Follicular lymphoma: a historical overview.

van Besien K, Schouten H. van Besien K, et al. Leuk Lymphoma. 2007 Feb;48(2):232-43. doi: 10.1080/10428190601059746. Leuk Lymphoma. 2007. PMID: 17325883

5

Successful allogeneic transplantation of patients with suspected prior invasive mold infection.

Hill BT, Kondapalli L, Artz A, Smith S, Rich E, Godley L, Odenike O, Pursell KJ, Larson RA, Stock W, van Besien K. Hill BT, et al. Among authors: van besien k. Leuk Lymphoma. 2007 Sep;48(9):1799-805. doi: 10.1080/10428190701534390. Leuk Lymphoma. 2007. PMID: 17786717

6

Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.

Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Gordon MK, et al. Among authors: van besien k. Leuk Lymphoma. 2008 Mar;49(3):531-7. doi: 10.1080/10428190701799043. Leuk Lymphoma. 2008. PMID: 18297531

7

Late relapse following allogeneic transplant for chronic lymphocytic leukemia: how good are graft versus leukemia effects?

Nguyen V, van Besien K. Nguyen V, et al. Among authors: van besien k. Leuk Lymphoma. 2008 Sep;49(9):1651-2. doi: 10.1080/10428190802409948. Leuk Lymphoma. 2008. PMID: 18798096 No abstract available.

8

Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.

Poiré X, Artz A, Larson RA, Kline J, Odenike O, Rich E, Godley L, Stock W, van Besien K. Poiré X, et al. Among authors: van besien k. Leuk Lymphoma. 2009 Jan;50(1):85-91. doi: 10.1080/10428190802626624. Leuk Lymphoma. 2009. PMID: 19142796 Free PMC article.

9

Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.

van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS. van Besien K, et al. Leuk Lymphoma. 2009 Nov;50(11):1809-17. doi: 10.3109/10428190903200790. Leuk Lymphoma. 2009. PMID: 19821799

10

Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.

Poiré X, Kline J, Grinblatt D, Zimmerman T, Conner K, Muhs C, Gajewski T, Van Besien K, Smith SM. Poiré X, et al. Among authors: van besien k. Leuk Lymphoma. 2010 Jul;51(7):1241-50. doi: 10.3109/10428194.2010.486876. Leuk Lymphoma. 2010. PMID: 20496994 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

332 results

Search Page